
Conference Coverage
Latest News

A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea

July 2026 in Pain Management: 10 Developments That Advanced and Challenged Patient Care

July 2026 in Hematology: 15 Developments That Advanced—and Challenged—Patient Care

Five Solid Tumor Advances That Defined July 2026

AZTEC Trial Finds SABR Schedules Do Not Meet PFS Benchmark With Atezolizumab in Advanced TNBC

Shorts










Continuing Education
All News

A 19-protein plasma panel predicted whether and when presymptomatic carriers of ALS-associated pathogenic variants would develop clinically manifest disease more accurately than neurofilament light chain alone.

Modern pharmacists increasingly serve as translators, helping patients navigate health care complexity, reduce confusion, and improve understanding through meaningful conversations.

FDA advisory vote boosts access hopes for peptide supporters, but compounding stays illegal pending rulemaking.

Preclinical data show a GLP-1 receptor agonist reprogrammed lung macrophages and prevented post-COVID pulmonary fibrosis in diabetic mice.

FDA clears ensitrelvir oral postexposure pill to prevent symptomatic COVID-19 after close contact, cutting infections in household trial with comparable safety.

Although the FDA committee's vote does not change what is currently legally available, it signals where the regulatory landscape is heading in the future.

The FDA approved SimpleScreen CRC, a blood-based screening test for average-risk adults aged 45 and older, potentially expanding screening access.

Agitation associated with Alzheimer disease carries clinical challenges, and Auvelity's approval can reshape treatment selection, safety monitoring, and the pharmacist's role.

Erica Marini, PharmD, and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Food as Medicine programs that do not include pharmacist-led food-drug interaction screening are clinically incomplete.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Taking a new medication is a step toward healing, but danger may lie in how different drugs, supplements, and even foods and drinks react behind the scenes.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Most websites selling GLP-1 receptor agonists prescribed medication with minimal clinical vetting, raising safety concerns pharmacists should be aware of.

Pharmacists can use motivational interviewing as a technique to encourage influenza vaccination.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

Pharmacists can provide updated vaccine recommendations and offer immunizations during MTM consults.

The review combines mechanistic and real-world evidence to guide health care professionals through different scenarios in the MS treatment space.

Brendon Neuen, PhD, MBBS, discusses findings from the FIND-CKD study showing that finerenone benefits patients with nondiabetic chronic kidney disease (CKD) and glomerular disease, as well as those receiving combination SGLT2i therapy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium, for up to 12 hours of relief from minor aches and pains in patients 12 years and older.

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

A yearlong trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.































